- 【Updated on May 12, 2025】 Integration of CiNii Dissertations and CiNii Books into CiNii Research
- Trial version of CiNii Research Automatic Translation feature is available on CiNii Labs
- Suspension and deletion of data provided by Nikkei BP
- Regarding the recording of “Research Data” and “Evidence Data”
Real-World Predictors of Severe Neutropenia Associated with Palbociclib and Endocrine Therapy for Metastatic Breast Cancer in Japanese Patients
-
- Takada Shinya
- Department of Pharmacy, National Hospital Organization Hokkaido Cancer Center
-
- Maeda Hideki
- Department of Breast Surgery, National Hospital Organization Hokkaido Cancer Center
-
- Umehara Kengo
- Department of Pharmacy, National Hospital Organization Hokkaido Cancer Center
-
- Kuwahara Sayuri
- Department of Breast Surgery, National Hospital Organization Hokkaido Cancer Center
-
- Yamamoto Mitsugu
- Department of Breast Surgery, National Hospital Organization Hokkaido Cancer Center
-
- Tomioka Nobumoto
- Department of Breast Surgery, National Hospital Organization Hokkaido Cancer Center
-
- Watanabe Kenichi
- Department of Breast Surgery, National Hospital Organization Hokkaido Cancer Center
-
- Mino Kozo
- Department of Pharmacy, National Hospital Organization Hokkaido Cancer Center
Search this article
Description
<p>Therapy for patients of metastatic breast cancer based on palbociclib, a cyclin-dependent kinase 4/6 inhibitor, has been approved in Japan. However, the risk factors for palbociclib-induced severe neutropenia in Japanese patients are rarely reported. Hence, the present study is aimed to identify the risk factors for adverse events requiring palbociclib dose reduction or discontinuation, and to identify the factors necessary to identify a more stable strategy for treatment continuation. This retrospective cohort analysis included patients with advanced breast cancer treated with 125 mg/d palbociclib. We demonstrated that severe neutropenia required significant dose reduction or therapy cessation. Most (77%) of the patients had severe neutropenia within the three courses. Risk factors for grade 3 or higher included low neutrophil counts (< 3250 /µL) before treatment [odds ratio (OR) = 9.10, 95% confidence interval (CI) (2.80–29.41), p < 0.001] and high age-adjusted Charlson comorbidity index (> 9) [OR = 1.64, 95% CI (1.09–2.48), p = 0.018]. Thus, low baseline neutrophil counts and high values for Age-adjusted Charlson comorbidity index are prospective predictive markers for palbociclib-induced severe neutropenia.</p>
Journal
-
- Biological and Pharmaceutical Bulletin
-
Biological and Pharmaceutical Bulletin 46 (8), 1105-1111, 2023-08-01
The Pharmaceutical Society of Japan
